Avadel Pharmaceuticals plc (AVDL)
- Previous Close
15.25 - Open
15.20 - Bid 15.09 x 600
- Ask 15.15 x 200
- Day's Range
14.95 - 15.60 - 52 Week Range
9.50 - 19.09 - Volume
592,466 - Avg. Volume
944,896 - Market Cap (intraday)
1.454B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.82 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.65
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
www.avadel.com154
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AVDL
Performance Overview: AVDL
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVDL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVDL
Valuation Measures
Market Cap
1.45B
Enterprise Value
1.37B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.91
Price/Book (mrq)
18.55
Enterprise Value/Revenue
24.81
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-284.42%
Return on Assets (ttm)
-54.91%
Return on Equity (ttm)
-779.92%
Revenue (ttm)
55.14M
Net Income Avi to Common (ttm)
-156.83M
Diluted EPS (ttm)
-1.82
Balance Sheet and Cash Flow
Total Cash (mrq)
88.79M
Total Debt/Equity (mrq)
46.87%
Levered Free Cash Flow (ttm)
-118M
Research Analysis: AVDL
Company Insights: AVDL
AVDL does not have Company Insights